


Fig. 1




Best Available Copy

10/520781

2/26

Fig. 2




F4/80: staining by microglia cell-specific antibody

RCA-1: Ricinus communis agglutinin-1 lectin

10/520781


3/26

Fig. 3



GFAP: staining by astroglia-specific antibody

Fig. 4



10/520781

5/26

Fig. 5






Fig. 6



7/26



Fig. 7





10/520781

8/26

Fig. 8




stained with hematoxylin-eosin



10/520781

9/26

Fig. 9




stained with H-PGDS-specific antibody

10/520781




10/26

Fig. 10



GFAP : stained with astroglia-specific antibody

Fig. 11




HE: stained with hematoxylin-eosin

GFAP: stained with astroglia-specific antibody

DPR: stained with DP receptor-specific antibody

Fig. 12




HE: stained with hematoxylin-eosin

GFAP: stained with astroglia-specific antibody

F4/80: stained with microglia cell-specific antibody

Fig. 13



CML: cerebellum molecular layer

CGL: cerebellum granular layer

CWM: cerebellum white matter

GFAP: stained with astroglia-specific antibody

Fig. 14





Fig. 15

Administered with HQL-79



(stained with hematoxylin-eosin)

Control






Fig. 16



HE: stained with hematoxylin-eosin

GFAP: stained with astroglia-specific antibody

Fig. 17



HE: stained with hematoxylin-eosin

GFAP: stained with astroglia-specific antibody

Fig. 18




Fig. 19




Fig. 20




Fig. 21








Fig. 22

Control

Group administered  
with HQL-79

GFAP



HE: stained with hematoxylin-eosin

GFAP: stained with astroglia-specific  
antibody

22/26

Fig. 23





Fig. 24




10/5/20781

24/26

Fig. 25

Control




administered with pinagladin

---

Before 1 hr and after 1 day



After 3 hrs and after 1 day



(stained with hematoxylin-eosin)

Fig. 26





Fig. 27



**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**